General SLE
Lupus Nephritis
Pregnancy
Skin

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

First posted November 8, 2022; Updated December 9, 2022; Recruiting

CATEGORIES: Lupus Nephritis

The Phase 3 study will assess atacicept vs. placebo on the impact of renal (kidney) function. Safety and patient reported outcomes will be clinically assessed. The clinical study is comprised of a 104 week double-blind treatment period, followed by a 52 week open-label treatment period and a 26 week safety follow-up period.

To Learn More Contact:

Vera Therapeutics by phone at 650-770-0077 or email at clinicaltrials@veratx.com.

ClinicalTrials.gov identifier (NCT number): NCT05609812

 

Learn More

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis

CATEGORIES: Lupus Nephritis

September 16, 2022

CATEGORIES: Lupus Nephritis

First posted September 15, 2022, Updated September 15, 2022

This trial aims to learn about the safety and tolerability of daxdilimab (trial drug), and to learn about the effect it has on lupus nephritis when combined with standard treatment (that is, mycophenolate mofetil [MMF] or mycophenolic acid [MPA] and corticosteroids [also called steroids, which are a type of anti-inflammatory drugs]) when compared to combination of placebo and standard treatment.

To Learn More Contact

Call Horizon Therapeutics at 1-866-479-6742 or by email to clinicaltrials@horizontherapeutics.com

ClinicalTrials.gov identifier (NCT number): NCT05540665

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (IRIS)

CATEGORIES: Lupus Nephritis

CATEGORIES: Lupus Nephritis

First posted November 30, 2021, Updated August 10, 2022; Recruiting

This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or without concomitant Class V).

To Learn More

Contact: AstraZeneca Clinical Study Information at 1-877-240-9479 or information.center@astrazeneca.com

ClinicalTrials.gov identifier (NCT number): NCT05138133

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

CATEGORIES: Lupus Nephritis

First posted September, 2020, Updated September, 2021; Recruiting
CATEGORIES: Lupus Nephritis

The objectives of this Phase 2, Double-Blind, Randomized, Placebo-Controlled Study is to evaluate the efficacy and safety of ravulizumab in adult participants With proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN)

To Learn More Contact
Contact: Alexion Pharmaceuticals, Inc.at 855-752-2356 or clinicaltrials@alexion.com
ClinicalTrials.gov identifier: NCT04564339

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)

CATEGORIES: Lupus Nephritis

The purpose of this trial is to evaluate the efficacy and safety of subcutaneous secukinumab 300 mg compared to placebo, in combination with standard of care therapy (SoC), in subjects with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features).

To Learn More Contact
Novartis Pharmaceuticals at 1-888-669-6682 or by email at novartis.email@novartis.com
ClinicalTrials.gov identifier: NCT04181762

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

CATEGORIES: Lupus Nephritis

CATEGORIES: Lupus Nephritis

The purpose of this study is to determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies.

To Learn More Contact
Reference Study ID Number: CA41705 www.roche.com/about_roche/roche_worldwide.htm
888-662-6728 (U.S. and Canada)
global.rochegenentechtrials@roche.com
ClinicalTrials.gov identifier: NCT04221477

A Phase 2 Safety and Efficacy Study of Filgotinib and GS-9876 in Participants with Lupus Membranous Nephropathy (LMN)

First filed Sept. 2017, updated May 2020 - Completed

CATEGORIES: Lupus Nephritis

CATEGORIES: Lupus Nephritis

The purpose of thisPhase 3 study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).

To Learn More Contact
GS-US-437-4093@gilead.com 
ClinicalTrials.gov identifier: NCT03285711

Learn More